Chronic pain ran my daily life for years. With a background in Molecular and Cellular Biology and time at Boston University School of Medicine (I completed boards before leaving to grow a healthcare startup, later acquired by Datavant), I built my own care team rather than waiting for one to assemble itself.
The team that mattered: Dr. Rowan Paul, Dr. Ramon Cugat, Dr. Matt Cook, Dr. Jonathan Kuo, Dr. Dan Shadoan, and others. Detailed imaging, real diagnostics, and regenerative therapies aimed at the root of the injuries — joint damage layered on top of MCAS and hEDS — instead of masking symptoms.
A daily pain level of 9 is now a 1–2. I travel, I lift, I have a life. Several top centers told me this outcome wasn’t possible.
Why regenerative medicine fits this problem
Regenerative therapies work with the body’s repair mechanisms rather than overriding them. For joint degeneration, chronic inflammation, and soft-tissue injury, that means addressing the underlying damage instead of cycling through painkillers or stacking surgeries.
The trade-off is that these therapies require maintenance. They are not a one-time fix; they slow and partially reverse processes that aging continues to push the other direction.
The treatments that did the work
Stem cell therapy
“Stem cell therapy” covers a broad spectrum with different safety and efficacy profiles. Cells can be autologous (bone marrow, adipose) or allogeneic (umbilical cord, donor MSCs). Risks include adverse reactions to donor tissue and, in some preparations, tumor formation. The FDA classifies products as minimally manipulated (Section 361) or substantially manipulated (Section 351, regulated as drugs).
Globally the quality of trials varies. I would not pursue stem cell therapy in every jurisdiction that offers it — robust validation and regulatory oversight matter.
Common targets: joint degeneration (knees, hips), chronic tendon injury, ligament repair, hypermobile joint dysfunction.
Platelet-rich plasma (PRP)
Derived from your own blood, with platelets and growth factors concentrated and injected. Among the safest and most widely used regenerative options, with related preparations PRF and PRGF for specific use cases. The FDA clears the preparation devices (510(k)); it does not regulate the practice of medicine, and has not approved PRP for any specific condition.
Dr. Paul used PRP to treat my foot pain, spinal issues, and multiple other hEDS-driven injuries. Ultrasound-guided, precise, repeatable — and the reason I avoided a second spinal fusion.
Exosome therapy
Exosomes are extracellular vesicles (about 30–150 nm) released by many cell types, not just stem cells. They carry proteins, lipids, and genetic material (mRNA, microRNAs) and act as cell-to-cell messengers. Their role in healing is still under study but they appear to be significant mediators of regenerative processes and may carry less risk than some stem cell preparations.
Targets where I and others have used them: chronic inflammation and nerve pain, tendon and ligament repair, regenerative rejuvenation.
Regulatory note: exosome products are investigational and not FDA-approved in the U.S. Verify your provider’s source, processing, and handling before any procedure, and be especially skeptical of medical-tourism marketing.
Multimodal care: what filled the gaps
Beyond PRP, exosomes, and stem cell products, the integrative pieces mattered:
- Osteopathic manipulative treatment with Dr. Dan Shadoan — kept the structure aligned long enough for the tissue to hold.
- Traditional Chinese medicine techniques including Gua Sha for scar tissue.
- Red-light laser and shockwave therapy for inflammation and tissue support.
What made the approach work was that it targeted the whole person — repairing damage, building strength, and preventing the next injury — rather than treating one joint in isolation.
Where regenerative medicine sits in 2025
- Stem cells. Better harvesting and cultivation continue to improve outcomes for cartilage and joint regeneration.
- PRP / PRGF. Active research expanding indications for more complex conditions.
- Exosomes. A promising safety profile and growing clinical data; potential mainstream pain-management option as regulation catches up. More in exosome vs. stem cell therapy.
Disclaimer
Many regenerative therapies — exosomes, stromal vascular fraction (SVF), and several stem-cell-derived products — remain under FDA investigation. Work with qualified providers, verify compliance with FDA or EMA standards, and confirm ethical sourcing and safe preparation. This article is informational, not medical advice.